Antonijoan, Rosa María
Ferrero-Cafiero, Juan Manuel
Coimbra, Jimena
Puntes, Montse
Martínez-Colomer, Joan
Arévalo, María Isabel
Mascaró, Cristina
Molinero, Cesar
Buesa, Carlos
Maes, Tamara http://orcid.org/0000-0001-5104-6867
Funding for this research was provided by:
Oryzon Genomics
EUROSTARS-2/CDTI, Spanish Ministry of Science, Innovation and Universities. (CIIP-20152001/E9683)
Article History
Accepted: 12 February 2021
First Online: 23 March 2021
Declarations
:
: Conceptualization: RMA, TM, CMo, CB. Formal analysis: MIA, RMA, JMF-C, JM-C, JC. Funding acquisition: CB, TM. Investigation: RMA, JMF-C, JMC, JC, CMa, MIA. Methodology: TM. Project Administration: CMo, RMA. Resources: RMA, JMF-C, JM-C, JC. Supervision: RMA, CMo. Visualization: MIA. Original draft preparation: RMA, TM, MIA. All authors contributed to the review and editing of this article. All authors approved the content of the manuscript and take responsibility for the content of the article.
: The open access fee was paid by Oryzon Genomics, S.A. This study was funded by Oryzon Genomics, S.A. (the sponsor), and grant CIIP-20152001/E9683, EUROSTARS-2/CDTI, Spanish Ministry of Science, Innovation and Universities.
: RMA has received personal fees from Centre d’Investigació del Medicament, Institut de Recerca de l’Hospital de la Santa Creu© Sant Pau (IIB-Sant Pau) and Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. JMF-C, JC, MP, and JM-C have received personal fees from Centre d’Investigació del Medicament, Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona, Spain. MIA, CMa, CMo, CB, and TM have received personal fees from Oryzon Genomics, during the conduct of the study. In addition, CMa is listed as inventor on patent application WO2017/158136 (pending), assigned to Oryzon Genomics; CMo owns company shares on the stock exchange (Oryzon Genomics); and CB reports patent WO2012/013728 (issued in multiple countries), assigned to Oryzon Genomics. CB is executive director and shareholder of Oryzon Genomics. TM has received other compensation from the Alzheimer’s Drug Discovery Foundation, outside the submitted work; is listed as inventor in WO2017/158136 (pending), WO2017/212061 (issued in multiple countries), and WO2019/025588 (pending) and further reports patent WO2012/013728 (issued in multiple countries), all assigned to Oryzon Genomics; is executive director and shareholder of Oryzon Genomics; and is a member of the Scientific Review Board of the Alzheimer’s Drug Discovery Foundation, for which no compensation is received.
: This study was registered under EUDRACT No. 2015-003721-33 and carried out in accordance with the protocol CL01-ORY-2001 and good clinical practices (Declaration of Helsinki, guideline ICH CPMP/ICH/135/95, European Directive 2001/20/EC, and Spanish RD 561/1993 and RD 223/2004). The study protocol and informed consent forms were approved by the Spanish Agency for Medicines and Health Products and the institutional review board.
: Written informed consent was obtained from all candidate subjects participating in this study before any clinical procedures were undertaken.
: The written informed consent allows publication of the data included in this manuscript.
: Materials can be obtained through a material transfer agreement upon reasonable request. The KDM1A Target Engagement Method validation protocol and report are available upon request. Access to the full trial protocol and clinical trial data can be obtained through a data-sharing agreement upon reasonable request and in compliance with applicable laws. Contact the corresponding author or email info@oryzon.com.
: Not applicable.